Novo Nordisk A/S vs Simon Property Group Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Simon Property Group Inc trades at $227 (market cap $74.00B). The key difference: Novo Nordisk A/S is far larger — about 3× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| NVO | SPG | |
|---|---|---|
Market Cap | $220.53B | $74.00B |
Sector | Health | Real Estate |
52-Week High | $71.70 | $228.70 |
52-Week Low | $35.29 | $160.68 |
Enterprise Value | $239.49B | $102.48B |
Dividend Yield | 3.63% | 3.86% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →